SG11201703639QA - Selective reduction of cysteine residues in il-17 antibodies - Google Patents

Selective reduction of cysteine residues in il-17 antibodies

Info

Publication number: SG11201703639QA
Authority: SG; Singapore
Prior art keywords: antibodies; cysteine residues; selective reduction; selective; reduction
Prior art date: 2014-12-22

Application number

SG11201703639QA

Inventor

Markus Heitzmann

Johann Winkler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-22

Filing date

2015-12-21

Publication date

2017-07-28

2015-12-21 Application filed by Novartis Ag filed Critical Novartis Ag

2017-07-28 Publication of SG11201703639QA publication Critical patent/SG11201703639QA/en

Links

125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG11201703639QA 2014-12-22 2015-12-21 Selective reduction of cysteine residues in il-17 antibodies SG11201703639QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462095361P	2014-12-22	2014-12-22
PCT/IB2015/059824 WO2016103146A1 (en)	2014-12-22	2015-12-21	Selective reduction of cysteine residues in il-17 antibodies

Publications (1)

Publication Number	Publication Date
SG11201703639QA true SG11201703639QA (en)	2017-07-28

Family

ID=55135470

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201703639QA SG11201703639QA (en)	2014-12-22	2015-12-21	Selective reduction of cysteine residues in il-17 antibodies

Country Status (15)

Country	Link
US (2)	US11292833B2 (en)
EP (2)	EP4389143A2 (en)
JP (3)	JP7021950B2 (en)
KR (2)	KR20230159617A (en)
CN (4)	CN114316044A (en)
AR (1)	AR103172A1 (en)
AU (1)	AU2015370515B2 (en)
BR (1)	BR112017010069A2 (en)
CA (1)	CA2971541A1 (en)
IL (2)	IL298761A (en)
MX (1)	MX2017008410A (en)
PH (1)	PH12017500967A1 (en)
RU (2)	RU2765307C2 (en)
SG (1)	SG11201703639QA (en)
WO (1)	WO2016103146A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3041533A1 (en)	2016-11-07	2018-05-11	Seattle Genetics, Inc.	Distribution of engineered-cysteine caps
WO2020037016A1 (en) *	2018-08-15	2020-02-20	Bristol-Myers Squibb Company	Protein fragmentation control strategy by re-oxidation in downstream chromatography
CN109369806B (en) *	2019-01-14	2019-04-19	迈威(上海)生物科技有限公司	The minimizing technology of cysteine variant in Su Jin monoclonal antibody product
EP4255927A1 (en) *	2020-12-02	2023-10-11	Fresenius Kabi Deutschland GmbH	Methods of selectively reducing antibodies
CA3205650A1 (en) *	2020-12-22	2022-06-30	Novartis Ag	Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
CN113189184B (en) *	2021-04-28	2022-09-09	浙江大学	Capillary gel electrophoresis sample buffer solution containing cysteine
WO2023067626A1 (en) *	2021-10-20	2023-04-27	Dr. Reddy's Laboratories Limited	A cell culture process to produce an antibody composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4766205A (en)	1985-11-13	1988-08-23	Beatrice Companies, Inc.	Method for isolation of recombinant polypeptides in biologically active forms
JP2669859B2 (en) *	1987-08-04	1997-10-29	協和醗酵工業株式会社	Protein reactivation method
JP3610395B2 (en) *	1991-08-26	2005-01-12	敏一中村	Mature hepatocyte growth factor
CZ20032208A3 (en)	2001-02-23	2004-01-14	Immunex Corporation	Increased yield of active proteins
US20050123532A1 (en) *	2001-12-04	2005-06-09	Takaharu Kouno	Method of activating protein
DE60327715D1 (en)	2002-12-20	2009-07-02	Mitsubishi Tanabe Pharma Corp	PROCESS FOR THE PROTECTION OF THIOL GROUPS IN ANTIBODIES
GB0417487D0 (en) *	2004-08-05	2004-09-08	Novartis Ag	Organic compound
NZ554520A (en)	2004-10-22	2010-03-26	Amgen Inc	Methods for refolding of recombinant antibodies
EP1893632B1 (en) *	2005-06-17	2015-08-12	Novo Nordisk Health Care AG	Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
GB0513852D0 (en)	2005-07-06	2005-08-10	Celltech R&D Ltd	Biological products
WO2007117749A2 (en)	2006-01-31	2007-10-18	Novartis Ag	Il-17 antagonistic antibodies fpr treating cancer
JP5364382B2 (en)	2006-02-07	2013-12-11	シャイアーヒューマンジェネティックセラピーズインコーポレイテッド	Stabilized composition of a protein having a free thiol moiety
LT3327026T (en)	2007-07-09	2019-11-11	Genentech Inc	Prevention of disulfide bond reduction during recombinant production of polypeptides
US20110033378A1 (en)	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
PL2896404T3 (en) *	2009-06-04	2017-12-29	Novartis Ag	Methods for identification of sites for IgG conjugation
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
KR101620771B1 (en)	2010-10-08	2016-05-12	노파르티스 아게	Methods of treating psoriasis using il-17 antagonists
AU2014259523B2 (en) *	2010-11-05	2016-02-04	Novartis Ag	Methods of treating psoriatic arthritis using IL-17 antagonists
WO2012082573A1 (en) *	2010-12-13	2012-06-21	Novartis Ag	Predictive methods and methods of treating arthritis using il-17 antagonists
JP5782279B2 (en)	2011-01-20	2015-09-24	株式会社Ｓｃｒｅｅｎホールディングス	Substrate processing method and substrate processing apparatus
EP3674320A3 (en)	2011-10-27	2020-08-12	Genmab A/S	Production of heterodimeric proteins
AU2012341081B2 (en) *	2011-11-21	2015-06-04	Novartis Ag	Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
AR103173A1 (en)	2014-12-22	2017-04-19	Novarits Ag	PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17

2015
- 2015-12-18 AR ARP150104191A patent/AR103172A1/en unknown
- 2015-12-21 KR KR1020237038206A patent/KR20230159617A/en active Application Filing
- 2015-12-21 BR BR112017010069A patent/BR112017010069A2/en not_active Application Discontinuation
- 2015-12-21 US US15/538,266 patent/US11292833B2/en active Active
- 2015-12-21 MX MX2017008410A patent/MX2017008410A/en unknown
- 2015-12-21 CN CN202210002380.7A patent/CN114316044A/en active Pending
- 2015-12-21 CN CN202210002418.0A patent/CN114249826B/en active Active
- 2015-12-21 SG SG11201703639QA patent/SG11201703639QA/en unknown
- 2015-12-21 RU RU2020113344A patent/RU2765307C2/en active
- 2015-12-21 CN CN202111452382.8A patent/CN114010780B/en active Active
- 2015-12-21 JP JP2017551390A patent/JP7021950B2/en active Active
- 2015-12-21 IL IL298761A patent/IL298761A/en unknown
- 2015-12-21 IL IL251893A patent/IL251893B2/en unknown
- 2015-12-21 CN CN201580066406.2A patent/CN107001460B/en active Active
- 2015-12-21 EP EP24170348.7A patent/EP4389143A2/en active Pending
- 2015-12-21 WO PCT/IB2015/059824 patent/WO2016103146A1/en active Application Filing
- 2015-12-21 AU AU2015370515A patent/AU2015370515B2/en active Active
- 2015-12-21 CA CA2971541A patent/CA2971541A1/en active Pending
- 2015-12-21 KR KR1020177016755A patent/KR102643328B1/en active IP Right Grant
- 2015-12-21 EP EP15823803.0A patent/EP3237445A1/en active Pending
- 2015-12-21 RU RU2017126025A patent/RU2719563C2/en active
2017
- 2017-05-25 PH PH12017500967A patent/PH12017500967A1/en unknown
2022
- 2022-02-04 JP JP2022016666A patent/JP2022062194A/en active Pending
- 2022-03-01 US US17/683,888 patent/US20220315650A1/en active Pending
2023
- 2023-06-01 JP JP2023091199A patent/JP2023110026A/en active Pending

Also Published As

Publication number	Publication date
US20170369567A1 (en)	2017-12-28
EP3237445A1 (en)	2017-11-01
RU2719563C2 (en)	2020-04-21
CN114010780B (en)	2022-08-02
IL251893B2 (en)	2023-11-01
BR112017010069A2 (en)	2018-02-06
WO2016103146A1 (en)	2016-06-30
CN107001460A (en)	2017-08-01
RU2017126025A3 (en)	2019-11-12
US20220315650A1 (en)	2022-10-06
IL298761A (en)	2023-02-01
KR20170088906A (en)	2017-08-02
CN107001460B (en)	2022-01-21
AU2015370515A1 (en)	2017-05-18
CA2971541A1 (en)	2016-06-30
KR102643328B1 (en)	2024-03-11
AU2015370515B2 (en)	2018-11-22
JP2022062194A (en)	2022-04-19
CN114316044A (en)	2022-04-12
AR103172A1 (en)	2017-04-19
RU2017126025A (en)	2019-01-24
JP7021950B2 (en)	2022-02-17
IL251893A0 (en)	2017-06-29
RU2020113344A (en)	2020-09-02
JP2023110026A (en)	2023-08-08
IL251893B1 (en)	2023-02-01
RU2020113344A3 (en)	2021-11-29
US11292833B2 (en)	2022-04-05
CN114249826B (en)	2024-02-02
CN114249826A (en)	2022-03-29
MX2017008410A (en)	2017-10-19
EP4389143A2 (en)	2024-06-26
CN114010780A (en)	2022-02-08
PH12017500967A1 (en)	2017-10-18
RU2765307C2 (en)	2022-01-28
JP2018507250A (en)	2018-03-15
KR20230159617A (en)	2023-11-21

Publication	Publication Date	Title
HK1255067A1 (en)	2019-08-02	Anti-c10orf54 antibodies and uses thereof
HK1243440A1 (en)	2018-07-13	Anti-interleukin-33 antibodies and uses thereof
HK1243102A1 (en)	2018-07-06	Anti-cd79b antibodies and methods of use
HRP20181359T1 (en)	2018-10-19	Anti-jagged1 antibodies and methods of use
IL251868B (en)	2021-09-30	Anti-tim3 antibodies and methods of use
ZA201605894B (en)	2019-07-31	Anti-egfrviii antibodies and uses thereof
HK1231400A1 (en)	2017-12-22	Selective reduction of proteins
IL251165A0 (en)	2017-04-30	Anti-il-1beta antibodies and methods of use
IL251893A0 (en)	2017-06-29	Selective reduction of cysteine residues in il-17 antibodies
IL247002A0 (en)	2016-09-29	Anti-il-13/il-17 bispecific antibodies and uses thereof
IL247315B (en)	2021-07-29	Anti-acth antibodies and use thereof
ZA201701663B (en)	2023-04-26	Anti-il-25 antibodies and uses thereof
IL251286A0 (en)	2017-05-29	Anti-pdgf-b antibodies and methods of use